AVEED Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aveed, and what generic alternatives are available?
Aveed is a drug marketed by Endo Operations and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-two patent family members in thirty-eight countries.
The generic ingredient in AVEED is testosterone undecanoate. There are sixty-nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.
DrugPatentWatch® Generic Entry Outlook for Aveed
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 14, 2027. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There is one tentative approval for the generic drug (testosterone undecanoate), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AVEED?
- What are the global sales for AVEED?
- What is Average Wholesale Price for AVEED?
Summary for AVEED
International Patents: | 52 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 55 |
Patent Applications: | 1,450 |
Drug Prices: | Drug price information for AVEED |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for AVEED |
What excipients (inactive ingredients) are in AVEED? | AVEED excipients list |
DailyMed Link: | AVEED at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AVEED
Generic Entry Date for AVEED*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAMUSCULAR |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for AVEED
Drug Class | Androgen |
Mechanism of Action | Androgen Receptor Agonists |
Paragraph IV (Patent) Challenges for AVEED
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
AVEED | Injection | testosterone undecanoate | 250 mg/mL | 022219 | 1 | 2014-06-11 |
US Patents and Regulatory Information for AVEED
AVEED is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of AVEED is ⤷ Subscribe.
This potential generic entry date is based on patent 7,718,640.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo Operations | AVEED | testosterone undecanoate | INJECTABLE;INTRAMUSCULAR | 022219-001 | Mar 5, 2014 | RX | Yes | Yes | 8,338,395 | ⤷ Subscribe | ⤷ Subscribe | ||||
Endo Operations | AVEED | testosterone undecanoate | INJECTABLE;INTRAMUSCULAR | 022219-001 | Mar 5, 2014 | RX | Yes | Yes | 7,718,640 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for AVEED
See the table below for patents covering AVEED around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 602004001893 | ⤷ Subscribe | |
Costa Rica | 7999 | METODOS Y COMPOSICIONES FARMACEUTICAS PARA LA OBTENCION CONFIABLE DE NIVELES ACEPTABLES DE TESTOSTERONA EN SUERO | ⤷ Subscribe |
Hong Kong | 1069325 | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels | ⤷ Subscribe |
World Intellectual Property Organization (WIPO) | 2004080383 | ⤷ Subscribe | |
Serbia | 51537 | POSTUPCI I FARMACEUTSKI SASTAVI ZA POUZDANO POSTIZANJE PRIHVATLJIVIH NIVOA SERUMA TESTOSTERONA (METHODS AND PHARMACEUTICAL COMPOSITIONS FOR RELIABLE ACHIEVEMENT OF ACCEPTABLE SERUM TESTOSTERONE LEVELS) | ⤷ Subscribe |
Eurasian Patent Organization | 200501819 | СПОСОБЫ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ ДОСТОВЕРНОГО ДОСТИЖЕНИЯ ПРИЕМЛЕМЫХ УРОВНЕЙ ТЕСТОСТЕРОНА В СЫВОРОТКЕ | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
AVEED Market Analysis and Financial Projection Experimental
More… ↓